Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04248023 |
Other study ID # |
HM20016728 |
Secondary ID |
1R18HS027077-01 |
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
July 15, 2020 |
Est. completion date |
May 31, 2023 |
Study information
Verified date |
July 2023 |
Source |
Virginia Commonwealth University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Unhealthy alcohol use is the third leading preventable cause of death in the United States.
Yet, primary care physicians do not, on average, screen for and address unhealthy alcohol use
in their patient populations. By implementing practice changes to promote screening and
treatment, patients stand to reduce unhealthy alcohol use and benefit from improved health
outcomes. This project will provide a sample of Virginia primary care practices with a
practice facilitator, practice specific resources, education on screening and counseling, and
education on medication assisted therapy. The project will measure whether this change will
improve screening rates and promote reduction of unhealthy alcohol use.
Description:
Unhealthy alcohol use is the third leading cause of preventable death in the US. Evidence
shows that screening for unhealthy alcohol use and providing persons engaged in risky
drinking with brief behavioral counseling interventions improves health outcomes,
collectively termed screening and brief intervention (SBI). For moderate or severe alcohol
use disorder (AUD), medication assistance therapy (MAT) is effective. Despite clear evidence
of effectiveness, only 13% of primary care patients are screened with a standard instrument
and only 6.7% of adults with AUD receive treatment. We believe that underutilization of SBI
and MAT are driven by both a misunderstanding of the role and effectiveness of primary care
in addressing unhealthy alcohol and limited practice resource and infrastructure. To promote
the dissemination and implementation of evidence-based strategies to address unhealthy
alcohol use throughout Virginia, we have extended our EvidenceNow collaboration to include
addiction medicine experts at Virginia Commonwealth University, the Virginia Ambulatory Care
Outcomes Research Network (ACORN), our state's family medicine residency training programs,
and our state's Community Service Boards. We propose a practice-level cluster randomized
trial with wait list control. 125 primary care practices in five regions throughout the
state, each centered around a residency site for educational support, will receive a practice
facilitation intervention to implement screening, counseling, and treatment for unhealthy
alcohol at intervention start or 6-month delay. Guided by the identified EvidenceNow key
drivers for change, practice support will include practice facilitation, education and
training, shared learning and best practices, screening and counseling toolkits, data
support, and assessment with feedback. Each practice will identify a clinician, nurse, and
administrator champion to locally lead efforts and participate in learning collaboratives.
Practices will design and implement screening, counseling, and treatment processes and
operational changes, adapting their implementation strategy based on experiences and findings
from other sites. We will conduct a mixed methods analysis. Primary outcomes will include the
increase in screening for unhealthy alcohol use, increase in provision of brief counseling
interventions and MAT, and reduction in alcohol intake for patients after practices receive
practice facilitation. We will use the consolidated framework for implementation research to
code and rate practice facilitation (e.g. dose, mode, reach) and practice implementation
strategies (e.g. SBI and MAT strategies and tools implemented) on outcomes. Data sources will
include practice facilitator field notes and interviews, chart reviews, patient survey,
clinician survey, All Payer Claims Data, and qualitative interviews. We will administer the
patient survey at baseline, 3 months, and 6 months after the intervention. Among patients age
18 to 75 with an office visit the prior month, we will randomly select 60 to survey. In
addition to our internal evaluation, we will participate in the external collaborative
evaluation and dissemination activities with AHRQ throughout the project.